PCM
AXSM icon

Palisade Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Palisade Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.86M Buy
+40,563
New +$7.01M 0.23% 126

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's AXSM Position: Q1 2026 in Review

Palisade Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 40,563 shares worth $6.86M. The stake represents 0.23% of the portfolio and ranks #126 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Palisade Capital Management held 40,563 shares of Axsome Therapeutics worth $6.86M as of Q1 2026.
  • Axsome Therapeutics was a new Palisade Capital Management position in Q1 2026.
  • Axsome Therapeutics made up 0.23% of Palisade Capital Management's portfolio in Q1 2026, its #126 holding.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.